Drug Profile

BT 02

Alternative Names: BT-02

Latest Information Update: 26 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BioTroy Therapeutics
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

07 Aug 2025 Biotroy Therapeutics plans a phase I trial for Non small cell lung cancer (Late-stage diseases, Metastatic diseases, Second-line therapy or greater; Inoperable/Unresectable) and Small cell lung cancer (Late-stage diseases, Second-line therapy or greater; Inoperable/Unresectable) in August 2025 (IV) (NCT07110363)
06 Aug 2025 Preclinical trials in Solid tumours in China (IV) prior to August 2025 (Biotroy Therapeutics pipeline, August 2025)
06 Aug 2025 Biotroy Therapeutics plans a phase-I trial for Malignant melanoma in China (IV), (NCT07107178)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com